[go: up one dir, main page]

DK1799633T3 - Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger - Google Patents

Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger

Info

Publication number
DK1799633T3
DK1799633T3 DK05770026.2T DK05770026T DK1799633T3 DK 1799633 T3 DK1799633 T3 DK 1799633T3 DK 05770026 T DK05770026 T DK 05770026T DK 1799633 T3 DK1799633 T3 DK 1799633T3
Authority
DK
Denmark
Prior art keywords
methylpropyl
dimethylamino
ethyl
active ingredient
pharmaceutical compositions
Prior art date
Application number
DK05770026.2T
Other languages
English (en)
Inventor
Andreas Fischer
Helmut Buschmann
Michael Gruss
Dagmar Lischke
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1799633(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1799633T3 publication Critical patent/DK1799633T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05770026.2T 2004-06-28 2005-06-27 Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger DK1799633T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
PCT/EP2005/006884 WO2006000441A2 (en) 2004-06-28 2005-06-27 Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (1)

Publication Number Publication Date
DK1799633T3 true DK1799633T3 (da) 2011-03-28

Family

ID=34925507

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04015091T DK1612203T3 (da) 2004-06-28 2004-06-28 Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
DK05770026.2T DK1799633T3 (da) 2004-06-28 2005-06-27 Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04015091T DK1612203T3 (da) 2004-06-28 2004-06-28 Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid

Country Status (27)

Country Link
US (16) US20070213405A1 (da)
EP (2) EP1612203B1 (da)
JP (1) JP4990764B2 (da)
KR (1) KR101096501B1 (da)
CN (1) CN1997621B (da)
AR (2) AR049949A1 (da)
AT (2) ATE368639T1 (da)
AU (1) AU2005256512B2 (da)
BR (2) BRPI0512792A (da)
CA (1) CA2572147C (da)
CY (2) CY1106929T1 (da)
DE (2) DE602004007905T2 (da)
DK (2) DK1612203T3 (da)
EC (1) ECSP17046065A (da)
ES (2) ES2291780T3 (da)
HR (1) HRP20110050T8 (da)
IL (1) IL180373A (da)
MX (1) MXPA06014741A (da)
NO (3) NO338605B1 (da)
NZ (1) NZ551605A (da)
PE (1) PE20060372A1 (da)
PL (2) PL1612203T3 (da)
PT (2) PT1612203E (da)
RU (1) RU2423345C2 (da)
SI (2) SI1612203T1 (da)
WO (1) WO2006000441A2 (da)
ZA (1) ZA200700774B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
PT1612203E (pt) * 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
LT2240431T (lt) * 2007-12-07 2017-04-10 Grünenthal GmbH (1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil) fenolio kristalinės modifikacijos
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
EP2997965B1 (en) 2009-07-22 2019-01-02 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
US20130116333A1 (en) 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
KR102146233B1 (ko) 2010-07-23 2020-08-21 그뤼넨탈 게엠베하 ３-(３-디메틸아미노-１-에틸-２-메틸-프로필)-페놀의 염 또는 공결정
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
BR112013022213A2 (pt) * 2011-03-04 2017-05-02 Gruenenthal Gmbh administração parenteral de tapentadol
ES2654407T3 (es) 2011-03-04 2018-02-13 Grünenthal GmbH Composición farmacéutica acuosa semisólida que contiene tapentadol
PT2680832T (pt) 2011-03-04 2019-10-28 Gruenenthal Gmbh Formulação farmacêutica aquosa de tapentadol para administração oral
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
US20160279078A1 (en) 2015-03-27 2016-09-29 Gruenenthal Gmbh Stable Formulation for Parenteral Administration of Tapentadol
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
PL3653599T3 (pl) 2016-04-19 2023-03-20 Ratiopharm Gmbh Krystaliczny fosforan tapentadolu
WO2018055070A1 (en) 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
EP4240735A1 (en) 2020-11-03 2023-09-13 Nimmune Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
CZ297679B6 (cs) * 1996-08-14 2007-03-07 G. D. Searle & Co. Krystalická forma B 4-[5-methyl-3-fenylizoxazol-4-yl]benzensulfonamidu
WO2002036542A1 (en) * 2000-10-31 2002-05-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
SI1426355T1 (sl) * 2001-09-13 2009-02-28 Kissei Pharmaceutical Kristali hidoksinorefedrinskega derivata
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
PT1612203E (pt) * 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''

Also Published As

Publication number Publication date
NO20160914A1 (no) 2007-01-24
HRP20110050T1 (hr) 2011-02-28
DK1612203T3 (da) 2007-12-03
NO343922B1 (no) 2019-07-08
SI1799633T1 (sl) 2011-05-31
ATE496021T1 (de) 2011-02-15
CN1997621A (zh) 2007-07-11
ES2291780T3 (es) 2008-03-01
DE602004007905D1 (de) 2007-09-13
CA2572147A1 (en) 2006-01-05
JP4990764B2 (ja) 2012-08-01
NO20070162L (no) 2007-01-24
RU2007103297A (ru) 2008-08-10
BR122018014454B8 (pt) 2021-07-27
CY1111530T1 (el) 2015-08-05
US20140296346A1 (en) 2014-10-02
US20200385334A1 (en) 2020-12-10
IL180373A (en) 2012-05-31
EP1799633B1 (en) 2011-01-19
BR122018014454B1 (pt) 2019-09-03
NZ551605A (en) 2010-01-29
ZA200700774B (en) 2008-09-25
NO20171103A1 (no) 2007-01-24
US20160122287A1 (en) 2016-05-05
MXPA06014741A (es) 2007-02-12
AU2005256512A1 (en) 2006-01-05
ECSP17046065A (es) 2018-11-30
US20190062263A1 (en) 2019-02-28
AU2005256512B2 (en) 2011-05-19
US20180230082A1 (en) 2018-08-16
CY1106929T1 (el) 2012-09-26
US20090186947A1 (en) 2009-07-23
PL1799633T3 (pl) 2011-06-30
DE602005026031D1 (de) 2011-03-03
WO2006000441A3 (en) 2006-05-04
US20200102261A1 (en) 2020-04-02
EP1612203B1 (en) 2007-08-01
US20110294898A1 (en) 2011-12-01
PT1799633E (pt) 2011-03-07
NO341239B1 (no) 2017-09-25
SI1612203T1 (sl) 2007-12-31
KR20070039929A (ko) 2007-04-13
NO338605B1 (no) 2016-09-12
PT1612203E (pt) 2007-08-20
US20100160447A1 (en) 2010-06-24
EP1799633A2 (en) 2007-06-27
KR101096501B1 (ko) 2011-12-20
US7994364B2 (en) 2011-08-09
EP1612203A1 (en) 2006-01-04
ATE368639T1 (de) 2007-08-15
WO2006000441A2 (en) 2006-01-05
DE602004007905T2 (de) 2008-05-08
AR049949A1 (es) 2006-09-20
US20210261492A1 (en) 2021-08-26
HRP20110050T8 (en) 2011-03-31
US20070213405A1 (en) 2007-09-13
PL1612203T3 (pl) 2007-12-31
CN1997621B (zh) 2011-06-15
US20140011886A1 (en) 2014-01-09
AR116052A2 (es) 2021-03-25
IL180373A0 (en) 2007-06-03
US20180029976A1 (en) 2018-02-01
BRPI0512792A (pt) 2008-04-08
JP2008504326A (ja) 2008-02-14
CA2572147C (en) 2012-10-30
US20230174458A1 (en) 2023-06-08
ES2359504T3 (es) 2011-05-24
US20170166515A1 (en) 2017-06-15
PE20060372A1 (es) 2006-05-08
US20120302643A1 (en) 2012-11-29
RU2423345C2 (ru) 2011-07-10

Similar Documents

Publication Publication Date Title
DK1799633T3 (da) Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
DK1786403T3 (da) Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DK2046724T3 (da) Fremgangsmåde til fremstilling af (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
DK1789405T3 (da) Nye enantiomerrene betaagonister, fremgangsmåder til deres fremstilling og deres anvendelse som lægemiddel
DK1732917T3 (da) Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel
DK2361609T3 (da) Formulering af småmolekylære lægemidler med forsinket frigivelse
DK1786785T3 (da) Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
DK1776010T3 (da) Fremgangsmåde til fremstilling af vandige aktivstofsammensætninger af aktivstoffer, som er tungt oplöselige i vand
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
DK1932522T3 (da) Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
FI20041129A0 (fi) Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
NL1028193A1 (nl) Farmaceutisch werkzame verbindingen.
DK1755562T3 (da) Kontraceptivum, som indeholder folsyre
EA200901387A1 (ru) Фармацевтическая композиция, включающая дезлоратадин
NO20074676L (no) Krystallinske former av (1 RS, 3RS, 6RS)-6-dimetylaminometyl-1-(3-metoksy-fenyl)cykloheksan-1,3-diol hydroklorid
EA200970167A1 (ru) Фармацевтическая композиция, содержащая комбинацию саредутанта и селективного ингибитора обратного захвата серотонина или ингибитора обратного захвата серотонина/норэпинефрина
NO20050391D0 (no) Nye fluorinerte benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem